| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Case Report |
| Article Title |
Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jia-Ping Qi, Huan Jiang, Teng Wu, Yuan Zhang, Wei Huang, Yi-Xuan Li, Jing Wang, Ju Zhang and Zhen-Hua Ying |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhen-Hua Ying, MM, Chief Doctor, Professor, Teacher, Center for General Practice Medicine, Department of Rheumatology and Immunology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, No. 158, Shangtang Road, Hangzhou 310000, Zhejiang Province, China. yingzh2021@163.com |
| Key Words |
Difficult-to-treat rheumatoid arthritis; Abatacept; Baricitinib; Combination therapy; Case report |
| Core Tip |
Although the combined use of Abatacept (ABT) and Janus kinase (JAK) inhibitors is not recommended in rheumatoid arthritis (RA) treatment guidelines, inflammatory cytokines have been found to compensate for the inhibitory effect of ABT on co-stimulatory signals, activate T-lymphocytes through the JAK/ Signal Transducers and Activators of Transcription (STAT) pathway, and promote the inflammatory response. In the treatment of this patient, Baricitinib, as a JAK inhibitor, combined with ABT can be used as a rescue treatment for difficult-to-treat RA, especially for patients with poor responses to single ABT treatment. |
| Publish Date |
2023-04-06 10:35 |
| Citation |
Qi JP, Jiang H, Wu T, Zhang Y, Huang W, Li YX, Wang J, Zhang J, Ying ZH. Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report. World J Clin Cases 2023; 11(11): 2474-2481 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i11/2474.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i11.2474 |
